Do you want to read an article? Please log in or register.
Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern
Lung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Implications of EGFR expression on EGFR signaling dependency and adaptive immunity against EGFR-mutated lung adenocarcinoma
Lung Cancer
Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, Miyakoshi J, Tateishi A, Igawa YS, Higashiyama RI, Mochizuki A, Masuda K, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamamoto R, Yamamoto N, Watanabe SI, Yatabe Y, Takahashi K, Kohno T, Ohe Y
doi: 10.1016/j.lungcan.2025.108494
SPECIAL REPORT
Lung, Respiratory and Thoracic Cancer
Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC
Lung, Respiratory and Thoracic Cancer
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study
Eur J Cancer
Dernbach G, Kazdal D, Ruff L, Alber M, Romanovsky E, Schallenberg S, Christopoulos P, Weis CA, Muley T, Schneider MA, Schirmacher P, Thomas M, Müller KR, Budczies J, Stenzinger A, Klauschen F
doi: 10.1016/j.ejca.2024.114292
Lung, Respiratory and Thoracic Cancer
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib Progression
Clin Lung Cancer
Wong WKY, Mok KKS, Tsui GPC, Chen OH, Loong HHF, Chan LL, Yan K, Mo F, Lee KWC, Lam KC, Mok FST, Johnson D, Chen ACC, Lam B, Lee M, Mok TSK, Li MSC
doi: 10.1016/j.cllc.2025.01.007
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Elghawy O, Heidlauf A, Yu C, Wang L, Yang D, Kurian M, Goel K, Rushkin L, Anran Huang A, Reed-Guy L, Bleiberg B, Sun L, Singh A, Cohen RB, Aggarwal C, Marmarelis M, Langer C
doi: 10.1016/j.lungcan.2024.107926
Lung, Respiratory and Thoracic Cancer
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations
Lung Cancer
Patil T, Gao D, Watson A, Sakamoto M, Nie Y, Gibson A, Dean ML, Yoder BA, Miller E, Stalker M, Aisner DL, Bunn PA, Schenk EL, Marmarelis ME, Bennati C, Navani V, Zhang Y, Camidge DR
doi: 10.1016/j.lungcan.2024.108040
Lung, Respiratory and Thoracic Cancer
Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3
J Thorac Oncol
Gray JE, Markovets A, Reungwetwattana T, Majem M, Nogami N, Peled N, Lee JS, Cho BC, Chewaskulyong B, John T, Han JY, Sebastian M, Todd A, Rukazenkov Y, Barrett C, Chmielecki J, Lee SM, Ramalingam SS, Hartmaier R
doi: 10.1016/j.jtho.2024.07.008
Lung, Respiratory and Thoracic Cancer
Optimizing Treatment Strategies for Egfr-Mutated Non-Small-Cell Lung Cancer Treated with Osimertinib: Real-World Outcomes and Insights
Cancers (Basel)
Thomas QD, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, Chouaid C, Lena H, Debieuvre D, Perol M, Quantin X
doi: 10.3390/cancers16213563
Lung, Respiratory and Thoracic Cancer
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Lancet Oncol
Wu YL, Guarneri V, Voon PJ, Lim BK, Yang JJ, Wislez M, Huang C, Liam CK, Mazieres J, Tho LM, Hayashi H, Nhung NV, Chia PL, de Marinis F, Raskin J, Zhou Q, Finocchiaro G, Le AT, Wang J, Dooms C, Kato T, Nadal E, Hin HS, Smit EF, Wermke M, Tan D, Morise M, O'Brate A, Adrian S, Pfeiffer BM, Stroh C, Juraeva D, Strotmann R, Goteti K, Berghoff K, Ellers-Lenz B, Karachaliou N, Le X, Kim TM, INSIGHT 2 investigators
doi: 10.1016/S1470-2045(24)00270-5